Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients

Table 7

Estimated average costs and effectiveness, comparing trabectedin and ifosfamide in advanced L-sarcoma and non-L-sarcoma.

Cost-effectiveness model	L-Sarcoma			Non-L-sarcoma
	Trabectedin	Ifosfamide	Difference	Trabectedin	Ifosfamide	Difference
Costs (all discounted)	€44,879	€24,797	€20,082	€27,497	€22,799	€4,698
(i) Drug acquisition	€31,597	€4,113	€27,484	€19,407	€3,660	€15,747
(ii) Drug administration	€5,298	€13,380	−€8,082	€3,646	€11,941	− €8,295
(iii) Nonrelated costs	€6,866	€5,464	€1,402	€3,325	€5,357	− €2,032
(iv) Adverse events costs	€1,119	€1,841	−€722	€1,119	€1,841	− €722
Effectiveness
(i) QALYs, discounted	1.025	0.773	0.251	0.516	0.781	−0.265
(ii) Preprogression LYs, undiscounted	0.646	0.423	0.223	0.386	0.476	−0.090
(iii) Postprogression LYs, undiscounted	0.902	0.758	0.144	0.371	0.694	−0.323
Cost-effectiveness ratios
(i) Costs per LY gained	€56,000			Ifosfamide dominant
(ii) Costs per QALY gained	€80,000			Ifosfamide dominant

QALYs: quality-adjusted life years; LY: life years.